[go: up one dir, main page]

AR121744A1 - MODULADORES DE a 1-ANTITRIPSINA - Google Patents

MODULADORES DE a 1-ANTITRIPSINA

Info

Publication number
AR121744A1
AR121744A1 ARP210100864A ARP210100864A AR121744A1 AR 121744 A1 AR121744 A1 AR 121744A1 AR P210100864 A ARP210100864 A AR P210100864A AR P210100864 A ARP210100864 A AR P210100864A AR 121744 A1 AR121744 A1 AR 121744A1
Authority
AR
Argentina
Prior art keywords
groups
alkyl
membered
hydroxy
substituted
Prior art date
Application number
ARP210100864A
Other languages
English (en)
Inventor
Simon Giroux
Michael John Boyd
Jr Robert Francis Fimognari
Mariam Zaky
Jr Ronald Lee Grey
Jinwang Xu
Sarathy Kesavan
Philippe Marcel Nuhant
Barrantes Pedro Manuel Garcia
Peter Jones
Michael Aaron Brodney
Diane Marie Boucher
Lev T D Fanning
Amy B Hall
Dennis James Hurley
Jr Mac Arthur Johnson
John Patrick Maxwell
Rebecca Jane Swett
Timothy Lewis Tapley
Stephen A Thomson
Veronique Damagnez
Kevin Michael Cottrell
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of AR121744A1 publication Critical patent/AR121744A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/10Expectorants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02Local antiseptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos y composiciones novedosos, y métodos novedosos para usarlos y prepararlos, que pueden ser útiles para tratar la deficiencia de a-1 antitripsina (AATD). Reivindicación 1: Un compuesto de la fórmula (1), un tautómero de este, un derivado deuterado de ese compuesto o tautómero, o una sal farmacéuticamente aceptable de cualquiera de los anteriores, caracterizado porque: Z¹ se selecciona de entre CRZ y N; RZ se selecciona de entre hidrógeno y halógeno; R¹ se selecciona de entre anillos aromáticos de 5 a 6 miembros y anillos heteroaromáticos de 5 a 6 miembros, cada uno de los cuales está sustituido con 0 - 2 grupos RA; cada RA se selecciona independientemente de entre halógeno, hidroxi, alquilo C₁₋₆, alcoxi C₁₋₆, y haloalcoxi C₁₋₆; R² se selecciona de entre grupos alquilo C₁₋₆, cicloalquilo C₃₋₆ y heterociclilo de 4 a 6 miembros, cada uno de los cuales está sustituido con 0 - 1 grupos RB; cada RB se selecciona independientemente de entre grupos halógeno, hidroxi, alcoxi C₁₋₆, alquilo C₁₋₆, y ciano; R³ se selecciona de entre grupos alquilo C₁₋₆, cicloalquilo C₃₋₇, y heterociclilo de 4 a 6 miembros, cada uno de los cuales está sustituido con 0 - 3 grupos RC; cada RC se selecciona independientemente de entre RY, grupos hidroxi, alcoxi C₁₋₆, alquilo C₁₋₆, y ácido carboxílico, en donde los grupos alquilo C₁₋₆ están sustituidos con 0 - 2 grupos seleccionados independientemente de entre oxo, hidroxi y ácido carboxílico, o dos grupos RC tomados juntos forman un grupo cicloalquilo de 3 a 6 miembros; y RY es un compuesto de fórmula (2).
ARP210100864A 2020-04-03 2021-04-05 MODULADORES DE a 1-ANTITRIPSINA AR121744A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063004636P 2020-04-03 2020-04-03

Publications (1)

Publication Number Publication Date
AR121744A1 true AR121744A1 (es) 2022-07-06

Family

ID=75690656

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100864A AR121744A1 (es) 2020-04-03 2021-04-05 MODULADORES DE a 1-ANTITRIPSINA

Country Status (13)

Country Link
US (1) US20230159580A1 (es)
EP (1) EP4126877A1 (es)
JP (1) JP2023520398A (es)
KR (1) KR20220163429A (es)
CN (1) CN115776984A (es)
AR (1) AR121744A1 (es)
AU (1) AU2021247282A1 (es)
BR (1) BR112022019794A2 (es)
CA (1) CA3179184A1 (es)
IL (1) IL296750A (es)
MX (1) MX2022012095A (es)
TW (1) TW202204359A (es)
WO (1) WO2021203010A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210089656A (ko) 2018-10-05 2021-07-16 버텍스 파마슈티칼스 인코포레이티드 알파-1 항트립신 조절제
UY38696A (es) 2019-05-14 2020-11-30 Vertex Pharma Moduladores de alfa-1 antitripsina
US12502376B2 (en) 2020-04-03 2025-12-23 Vertex Pharmaceuticals Incorporated Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD)
US20240012010A1 (en) 2020-11-12 2024-01-11 Vertex Pharmaceuticals Incorporated Methods of monitoring alpha-1 antitrypsin (aat) deficiency by measuring polymerised aat
CN116813623A (zh) * 2022-03-21 2023-09-29 东南大学 一种吡咯并[2,3-f]吲唑类化合物的制备方法
WO2024054624A1 (en) 2022-09-09 2024-03-14 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
WO2025236095A1 (en) * 2024-05-17 2025-11-20 Congruence Therapeutics Inc. Modulators of alpha-1 antitrypsin
WO2026014456A1 (ja) * 2024-07-10 2026-01-15 株式会社アークメディスン 化合物、補体d因子阻害剤、及び医薬組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3103920C (en) * 2018-06-22 2025-09-16 Ucl Business Ltd COMPOUNDS FOR TREATING DISEASES MEDIATED BY ALPHA-1 ANTITRYPSIN
KR20210089656A (ko) * 2018-10-05 2021-07-16 버텍스 파마슈티칼스 인코포레이티드 알파-1 항트립신 조절제
UY38696A (es) * 2019-05-14 2020-11-30 Vertex Pharma Moduladores de alfa-1 antitripsina
TW202116303A (zh) * 2019-10-02 2021-05-01 美商維泰克斯製藥公司 α—1抗胰蛋白酶缺乏症之治療方法

Also Published As

Publication number Publication date
US20230159580A1 (en) 2023-05-25
MX2022012095A (es) 2023-01-11
KR20220163429A (ko) 2022-12-09
JP2023520398A (ja) 2023-05-17
IL296750A (en) 2022-11-01
BR112022019794A2 (pt) 2022-12-06
CA3179184A1 (en) 2021-10-07
TW202204359A (zh) 2022-02-01
EP4126877A1 (en) 2023-02-08
WO2021203010A1 (en) 2021-10-07
AU2021247282A1 (en) 2022-10-27
CN115776984A (zh) 2023-03-10

Similar Documents

Publication Publication Date Title
AR121744A1 (es) MODULADORES DE a 1-ANTITRIPSINA
AR120896A1 (es) COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz
AR109958A1 (es) Lactamas bicíclicas de piridona y sus métodos de uso
AR117102A1 (es) Inhibidores de arg1 y/o arg2
AR119728A1 (es) Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4]tiadiazina como inhibidores de mrgx2
AR107714A1 (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
AR051026A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR126108A1 (es) Tratamientos para la degradación del braf mutante
AR094876A1 (es) Derivados de ácido betulínico modificados con alquilo c-3 y alquenilo
AR093077A1 (es) ANTAGONISTAS DE mGlu2/3 PARA EL TRATAMIENTO DE LOS TRASTORNOS AUTISTAS
AR109438A1 (es) Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus
BR9803497A (pt) Compostos, composições farmacêuticas, e processos para preparar os compostos e as composições e para tratar distúrbio do sistema nervoso central.
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
AR121745A1 (es) MODULADORES DE a-1 ANTITRIPSINA
AR118082A1 (es) Inhibidores de enzimas
AR109650A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
AR116464A1 (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
AR117037A1 (es) Compuestos pirazol para el tratamiento de enfermedades autoinmunitarias
AR115086A1 (es) Pirrolin-2-onas sustituidas con 2-bromo-6-alcoxifenilo y su uso como herbicidas
AR089853A1 (es) Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso
AR117122A1 (es) INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
AR116400A1 (es) Compuesto de imidazopiridinona
AR117539A1 (es) INHIBIDORES DE TGF-bR1 (ALK5) ÚTILES PARA TRATAR TRASTORNOS DE PROLIFERACIÓN CELULAR
AR123730A1 (es) Compuestos novedosos
AR118348A1 (es) 3-(2-bromo-4-alquinil-6-alcoxifenil)-3-pirrolin-2-onas y su uso como herbicidas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal